Proposed prognostic score for PFS for patients with WM treated with ibrutinib monotherapy
| Variables . | HR (95% CI) . | P . |
|---|---|---|
| CXCR4 mutations | 2.51 (1.28-4.89) | .001 |
| Platelet count <100 K/ul | 1.98 (1.17-3.36) | .07 |
| Variables . | HR (95% CI) . | P . |
|---|---|---|
| CXCR4 mutations | 2.51 (1.28-4.89) | .001 |
| Platelet count <100 K/ul | 1.98 (1.17-3.36) | .07 |
| Stratum . | Score . | n (%) . | Failed . | 5-y PFS rate, % (95% CI) . | HR (95% CI) . |
|---|---|---|---|---|---|
| Low | 0 | 144 (60) | 28 | 72 (60-82) | 1.0 (Ref) |
| Intermediate | 1 | 76 (32) | 25 | 44 (27-60) | 2.2 (1.3-3.8) |
| High | 2 | 21 (9) | 9 | 20 (1-55) | 4.7 (2.2-10.1) |
| Stratum . | Score . | n (%) . | Failed . | 5-y PFS rate, % (95% CI) . | HR (95% CI) . |
|---|---|---|---|---|---|
| Low | 0 | 144 (60) | 28 | 72 (60-82) | 1.0 (Ref) |
| Intermediate | 1 | 76 (32) | 25 | 44 (27-60) | 2.2 (1.3-3.8) |
| High | 2 | 21 (9) | 9 | 20 (1-55) | 4.7 (2.2-10.1) |